LBCTR2020030215已完成不适用
An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Merck KGaA
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •1. Patients with MS randomised in CLARITY/CLARITY-EXT clinical trial(s) who have received = 1 course of IMP (Cladribine Tablets or placebo).
- •Patients with their FCDE randomised in ORACLE MS clinical trial who have received= 1 course of IMP (Cladribine Tablets or placebo).
- •2. Informed Consent
排除标准
- •1. Medical Conditions:
- •Any condition, including any uncontrolled disease state other than MS, that in the Investigator’s opinion, constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or
- •evaluation.
- •For the MRI sub-study:
- •1. Female Participants Who are pregnant
- •2. Patient taking Cladribine Tablets as part of another study at the time of the start of this study
研究者
相似试验
尚未招募
不适用
Prospective study of the relationship between patient with high CRP levels and antibiotic therapyPatients with CRP values greater than 15 mg /JPRN-UMIN000027577ishi Saitama Chuo Hospital50
招募中
不适用
An observational study on treatment course in patients with whiplash-associated disordersWhiplash-associated disordersJPRN-UMIN000037881Hayaishi Hospital100
进行中（未招募）
3 期
A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyMetastatic or locally advanced nonsquamous NSCLC with an EGFR-activating mutationJPRN-jRCT2021220002Inoguchi Akihiro560
进行中（未招募）
1 期
A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene AbeparvovecMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003492-18-ESBiogen Idec Research Limited60
进行中（未招募）
1 期
A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene AbeparvovecMuscular Atrophy, SpinalMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003492-18-DEBiogen Idec Research Limited49